Blood coagulation in normotensives and hypertensives in relation to their body mass index;Gerinnung bei normotonikern und hypertonikern in abhängigkeit vom body mass index

Deutsche Medizinische Wochenschrift

Volumn 127, Issue 45, 2002, Pages 2374-2378

  Franz, Ingomar Werner ^a   Van der Meyden, J ^a   Tonnesmann U ^a   Muller J F M ^a   Rocker L ^b   Hopfenmuller W ^b  

^a Klinik Wehrawald   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR 8; D DIMER; FIBRIN MONOMER; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PADGEM PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD CLOTTING; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; FIBRINOLYSIS; HEART INFARCTION; HEMATOLOGICAL PARAMETERS; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; MALE; PARTIAL THROMBOPLASTIN TIME; RISK FACTOR; STROKE; SYSTOLIC BLOOD PRESSURE;

ADULT; BLOOD COAGULATION; BLOOD COAGULATION TESTS; BLOOD PRESSURE; BODY MASS INDEX; CEREBROVASCULAR ACCIDENT; CHOLESTEROL, HDL; FACTOR VIII; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; FIBRINOLYSIS; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; OBESITY; PARTIAL THROMBOPLASTIN TIME; PLASMINOGEN ACTIVATOR INHIBITOR 1; RISK FACTORS; TRIGLYCERIDES;

EID: 0037049030     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-35359     Document Type: Article

References (39)

1. Alessi MC, Juhan-Vague I, Kooistra T, Declerck PJ, Collen D. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular celline Hep G 2. Thromb Haemost 1988; 60: 491-494
2. Andrioli G. Study of platelet adhesion in patients with uncomplicated hypertension. J Hypertens 1996; 14: 1215-1221
3. Blann AD, Lip GY, Islim IF, Beevers DG. Evidence of platelet activation in hypertension. J Hum Hypertens 1997; 11: 607-609
4. Eriksson P, Reynisdottier S, Löhnqvist F et al. Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals. Diabetologia 1998; 41: 65-71
5. Fogari R. Mugellini A, Zoppi A et al. Effect of losartan and perindopril on plasma PAI-1 and fibrinogen in hypertensive type 2 diabetic patients. J Hypertens 1999; 17: 58(Suppl 3
6. Folsom AR, Quamhieh HT, Wing RR et al. Impact of weight lost on plasminogen activator inhibitor (PAI-1), factor VIII, and other hemostatic factors in moderately overweight adults. Arterioscler Thromb 1993; 13: 162
7. Franz I-W. Blood pressure measurement during ergometric stress testing. Z Kardiol 1996; 85 (Suppl 3); 71-75
8. Giansante C. Fibrinogen, D-dimer and thrombinantithrombin complexes in a random population sample: relationships with other cardiovascular risk factors. Thromb Haemost 1994; 71: 581-586
9. Goodfield NER, Newby DE, Ludlam CA, Flapan AD. Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure. Circulation 1999; 99: 2983-2985
10. Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Eng J Med 2000; 342: 145-153
11. Hrafukelsdottir T, Wall Ul, Jern C, Jern S. Impaired capacity for endogenous fibrinolysis in essential hypertension. Lancet 1998: 352: 1597-1598
12. Jansson JH, Boman K, Nilsson TK. Enalapril related changes in the fibrinolytic system in survivors of myocardial infarction. Eur J Clin Pharmacol 1993; 44: 485-488
13. Juhan-Vague I. Thompson SG, Jespersen J. Involvement of the hemostatic system in the insulin resistance syndrom: a study of 1,500 patients with angina pectoris. Aterioscler Thromb 1991; 13: 1865
14. Junker R, Heinrich J. Schulte H et al. Haemostasis in normotensive and hypertensive men: results of the PROCAM study. J Hypertens 1998; 16: 917-923
15. Kohler HP, Grant PJ. Plasminogen activator inhibitor typ 1 and coronary artery disease. N Engl J Med 2000; 342: 1792-1799
16. Landin K, Tengborn L, Smith U. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Int Med 1990; 227: 273-278
17. Lee AJ, Lowe GDO, Woodward M et al. Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease and family history: the Scottish Heart Health Study. Br Heart J 1993; 69: 338-342
18. Lemne C, de Faire U. Elevation of plasminogen activator inhibitor 1 in borderline hypertension is linked to concomitant metabolic disturbances. Eur J Clin Invest 1996; 26: 692-697
19. Blann AD. Does hypertension confer a prothrombotic state? Circulation 2000; 101: 218-220
20. Maknis TK, Tsoukala G, Krespi PG et al. Hemostasis balance disorders in patients with essential hypertension. Thromb Res 1997; 88: 99-107
21. Makris TK, Stavroulakis GA, Krespi PG et al. Fibrinolytic/hemostatic variables in arterial hypertension: response to treatment with irbesartan or atenolol. Am J Hypertens 2000; 13: 783-788
22. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342: 1076-1079
23. Montalescot G, Lollet JP, Choussat R, Thomas D. Fibrinogen as a risk factor for coronary heart disease. Eur Heart J 1998; 19: H11-H17(Suppl H
24. Müller JFM, Franz I-W. Is body mass index influence on cardiovascular risk factors identical in hypertensives and normotensives? J Hypertens 1998; 16 (Suppl 2); S265
25. Nordt T, Bode C. Endogene Fibrinolyse bei Diabetes mellitus und koronarer Herzkrankheit. Dtsch Ärztebl 2002; 99: 354-364
26. Norgaard K, Jensen T, Christensen P, Feldt-Rasmussen B. A comparison of Spirapril and isradipine in patients with diabetic nephropathy and hypertension. Blood Pressure 1993; 2: 301-308
27. Poli KA, Tofler GH, Larson MG et al. Association of blood pressure with fibrinolytic potention in the Framingham Offspring Population. Circulation 2000; 101: 264-269
28. Progress Collaborative Group. Randomised trial of a perindopril-based blood pressure lowering regimen among 6.105 individuais with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-1041
29. Ridker PM, Gaboury C, Conlin PR et al. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II - evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation 1993; 87: 1969
30. Ridker PM, Hennekens CH, Stampfer MJ et al. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet 1994; 343: 940-943
31. Rissanen P, Vachtera E, Krusius T et al. Weight change and blood coagulability and fibrinolysis in healthy obese woman. Int J Obes 2001; 25: 212-218
32. Sironi L, Calvio AM, Arnaboldi L et al. Effect of valsartan on angiotensin II induced plasminogen activator inhibitor-1 biosynthesis in artertial smooth muscle cells. Hypertension 2001; 37: 961-966
33. Tönnesmann U, Franz I-W. Beeinflussung von kardiovaskulären Risikofaktoren durch stationäre Rehabilitation - Die TOPAS-Studie. Praevention und Rehabilitation 1999; 4: 208-211
34. Van der Bom JG, De Knijff P, Haverkate F et al. Tissue plasminogen activator and risk of myocardial infarction: the Rotterdam Study. Circulation 1997; 95: 2623-2627
35. Van der Meyden J, Müller JFM, Franz I-W. The effect of body weight reduction on fibrinogen in hypertensives and normotensives and its relation to body mass index (BMI). Int J Sport Med 1999; 20: 12
36. Van der Meyden J, Tönnesmann U, Müller JFM, Röcker L, Franz I-W. Does body weight reduction alone and in combination with ACE-inhibitor influerice the disturbed balance between coagulation and fibrinolysis in obese hypertensives? J Hypertens 2001; 19 (Suppl 2); 70
37. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulares the expression of plasminogen activator inhibitor-1 in cultured endothelial cells: a potential link between the renin-angiotensin system and thrombosis. J Clin Invest 1995; 95: 995-1001
38. Vaughan DE, Rouleau JL. Ridker PM et al. on behalf of the HEART Study Investigators. Effects of ramipril on plasma fibrinolysis balance in patients with acure anterior myocardial infarction. Circulation 1997; 96: 442-447
39. Wright RA, Flapan AD, Albertin KGMM et al. Effects of captopril therapy on endogenous fibrinolysis in men with recent uncomplicated myocardial infarction. J Am Coll Cardiol 1994: 24: 67-73